XNASGOVXW
Market cap21mUSD
Jan 14, Last price
0.12USD
1D
-4.23%
1Q
-33.28%
Name
GeoVax Labs Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-40.38%
Revenues
0k
-100.00%
Net income
-26m
L+85.28%
CFO
-25m
L+32.28%
Earnings
Feb 26, 2025
Profile
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 81 -78.96% | ||||||||
Cost of revenue | 47,390 | 14,166 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (47,390) | (14,085) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (7) | ||||||||
Tax Rate | |||||||||
NOPAT | (47,390) | (14,078) | |||||||
Net income | (25,967) 85.28% | (14,015) -24.37% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 4,062 | 27,727 | |||||||
BB yield | -29.54% | -115.48% | |||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,748 | ||||||||
Net debt | (6,453) | (27,613) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (25,174) | (19,030) | |||||||
CAPEX | (49) | (134) | |||||||
Cash from investing activities | (49) | (134) | |||||||
Cash from financing activities | 4,062 | 35,353 | |||||||
FCF | (45,190) | (16,319) | |||||||
| Balance | |||||||||
Cash | 6,453 | 27,613 | |||||||
Long term investments | |||||||||
Excess cash | 6,453 | 27,609 | |||||||
Stockholders' equity | (104,362) | (78,371) | |||||||
Invested Capital | 110,125 | 104,971 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 2,540 | 2,540 | |||||||
Price | 5.42 -42.72% | 9.45 -82.59% | |||||||
Market cap | 13,753 -42.72% | 24,009 -82.59% | |||||||
EV | 7,301 | (3,604) | |||||||
EBITDA | (47,315) | (14,029) | |||||||
EV/EBITDA | 0.26 | ||||||||
Interest | 57 | ||||||||
Interest/NOPBT | |||||||||